Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

Medicine, Oncology, Pathology +15

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 599 citations · Full text

Medicine, Immunology, Oncology +12

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 381 citations · Full text

Medicine, Immunology, Oncology +17

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study

Caroline Houillier, Luc Taillandier, Sylvain Dureau et al. · Journal of Clinical Oncology · 2019 · 276 citations

Medicine, Oncology, Radiation Oncology +13

Management and outcome of primary CNS lymphoma in the modern era

Caroline Houillier, Carole Soussain, Hervé Ghesquières et al. · Neurology · 2020 · 245 citations · Full text

Medicine, Oncology, Chemotherapy +12